89 related articles for article (PubMed ID: 22704481)
1. Enzyme replacement therapy improves cardiac features and severity of Fabry disease.
Motwani M; Banypersad S; Woolfson P; Waldek S
Mol Genet Metab; 2012 Sep; 107(1-2):197-202. PubMed ID: 22704481
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age.
Parini R; Pintos-Morell G; Hennermann JB; Hsu TR; Karabul N; Kalampoki V; Gurevich A; Ramaswami U;
Drug Des Devel Ther; 2020; 14():2149-2158. PubMed ID: 32581513
[TBL] [Abstract][Full Text] [Related]
3. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation.
Lavalle L; Thomas AS; Beaton B; Ebrahim H; Reed M; Ramaswami U; Elliott P; Mehta AB; Hughes DA
PLoS One; 2018; 13(4):e0193550. PubMed ID: 29621274
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Clinical-Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy.
Frustaci A; Verardo R; Galea N; Alfarano M; Magnocavallo M; Marchitelli L; Sansone L; Belli M; Cristina M; Frustaci E; Russo MA; Chimenti C
J Am Heart Assoc; 2024 Apr; 13(8):e032734. PubMed ID: 38563373
[TBL] [Abstract][Full Text] [Related]
5. Fabry disease: development and progression of left ventricular hypertrophy despite long-term enzyme replacement therapy.
Maurizi N; Nowak A; Gruner C; Namdar M; Schmied C; Porretta AP; Barbey G; Monzambani V; Monney P; Barbey F
Heart; 2024 May; ():. PubMed ID: 38749654
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factors for development of left ventricular hypertrophy in Fabry disease.
Monda E; Bakalakos A; Lachmann R; Syrris P; Limongelli G; Murphy E; Hughes D; Elliott PM
Heart; 2024 May; 110(12):846-853. PubMed ID: 38688703
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Implications of Left Ventricular Hypertrophy and Mechanical Function in Fabry Disease: A Longitudinal Cohort Study.
Chang HC; Kuo L; Sung SH; Niu DM; Yu WC
J Am Soc Echocardiogr; 2024 May; ():. PubMed ID: 38704103
[TBL] [Abstract][Full Text] [Related]
8. Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA.
Lin HY; Chen MR; Lin SM; Hung CL; Niu DM; Chuang CK; Lin SP
Orphanet J Rare Dis; 2018 Aug; 13(1):148. PubMed ID: 30157891
[TBL] [Abstract][Full Text] [Related]
9. Late-onset Fabry disease: the cardiac sequela.
Tremblay J; Kim S; Philbin E; Beers K; Lightle A; Belov D
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35680278
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported experience with Fabry disease and its management in the real-world setting: results from a double-blind, cross-sectional survey of 280 respondents.
Berry L; Walter J; Johnson J; Alton J; Powers J; Llòria X; Koulinska I; McGee M; Laney D
Orphanet J Rare Dis; 2024 Apr; 19(1):153. PubMed ID: 38605390
[TBL] [Abstract][Full Text] [Related]
11. Differences Between Two Distinct Hypertrophic Cardiac Conditions: Fabry Disease versus Hypertrophic Cardiomyopathy.
Akhan O; Kış M; Güzel T; Zoghi M
Arq Bras Cardiol; 2024 Jan; 121(1):e20230229. PubMed ID: 38324858
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Implications of the Extent of Cardiac Damage in Patients With Fabry Disease.
Meucci MC; Lillo R; Del Franco A; Monda E; Iannaccone G; Baldassarre R; Di Nicola F; Parisi V; Lombardo A; Spinelli L; Biagini E; Pieroni M; Pisani A; Crea F; Iaccarino G; Limongelli G; Olivotto I; Graziani F
J Am Coll Cardiol; 2023 Oct; 82(15):1524-1534. PubMed ID: 37793750
[TBL] [Abstract][Full Text] [Related]
13. Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease.
Pogoda C; Brand SM; Duning T; Schmidt-Pogoda A; Sindermann J; Lenders M; Brand E
Front Cardiovasc Med; 2023; 10():1223635. PubMed ID: 38028489
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of papillary muscle hypertrophy in fabry disease.
Cianciulli TF; Saccheri MC; Llobera MN; Balletti LR; Beck MA; Morita LA; Lax JA
BMC Cardiovasc Disord; 2023 Aug; 23(1):424. PubMed ID: 37635225
[TBL] [Abstract][Full Text] [Related]
15. The clinical profiles of female patients with Fabry disease in Latin America: A Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status.
Martins AM; Cabrera G; Molt F; Suárez-Obando F; Valdés RA; Varas C; Yang M; Politei JM
JIMD Rep; 2019 Sep; 49(1):107-117. PubMed ID: 31497488
[TBL] [Abstract][Full Text] [Related]
16. Respiratory impairments in patients suffering from Fabry disease - A cross-sectional study.
Ahmed H; Backer V; Effraimidis G; Rasmussen ÅK; Kistorp CM; Feldt-Rasmussen U
Chron Respir Dis; 2024; 21():14799731231221821. PubMed ID: 38334083
[TBL] [Abstract][Full Text] [Related]
17. Rapidly progressive cognitive impairment resulting in heavy psychosocial burden in a patient with Fabry disease undergoing hemodialysis: a case report.
Ohsawa I; Onuki A; Oka F; Matsuoka Y; Makita Y; Kobayashi T; Kanaguchi Y; Nakamura Y; Suzuki Y; Goto Y; Gotoh H
BMC Nephrol; 2024 Jun; 25(1):188. PubMed ID: 38831308
[TBL] [Abstract][Full Text] [Related]
18. Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease.
Patel V; O'Mahony C; Hughes D; Rahman MS; Coats C; Murphy E; Lachmann R; Mehta A; Elliott PM
Heart; 2015 Jun; 101(12):961-6. PubMed ID: 25655062
[TBL] [Abstract][Full Text] [Related]
19. Histopathological evidence of Fabry disease in a female patient with left ventricular noncompaction.
Martins E; Pinho T; Carpenter S; Leite S; Garcia R; Madureira A; Oliveira JP
Rev Port Cardiol; 2014 Sep; 33(9):565.e1-6. PubMed ID: 25246064
[TBL] [Abstract][Full Text] [Related]
20. Fabry disease: multidisciplinary evaluation after 10 years of treatment with agalsidase Beta.
Juan P; Hernan A; Beatriz SA; Gustavo C; Antonio M; Eduardo T; Raul D; Margarita L; Mariana B; Daniela G; Marina S
JIMD Rep; 2014; 16():7-14. PubMed ID: 24850233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
